What's happening
This bill prohibits insurance policies from requiring prior authorization for antiretroviral drugs used to treat or prevent HIV/AIDS.
Why it matters
Removes bureaucratic barriers for patients needing antiretroviral (ARV) drugs. , which can be critical for quickly starting or continuing treatment for HIV/AIDS or for using these drugs as prevention (like PrEP). Delays can increase health risks and transmission.
Shifts more clinical decision-making power to doctors and patients. by preventing insurers from overruling or slowing down access to ARVs through prior authorization, which is often seen as a cost-control tool rather than a medical necessity.
May improve public health outcomes. by making it easier for people at risk of or living with HIV to access timely medication, potentially reducing new infections and improving adherence to treatment, which is key to individual and community health.
Could slightly increase insurance costs or premiums. because insurers lose a tool for managing medication spending, but it prioritizes immediate access to life-saving and prevention medications over administrative cost controls.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
No Delays for HIV Drugs
Plain English, a few words. Used as the page title.
Sponsors
3 Co-sponsors
History
- Signed chap.152
- Delivered to governor
- Returned to senate
- Passed assembly
- Ordered to third reading rules cal.301
- Substituted for A1619A
- Referred to ways and means
- Returned to assembly
- Repassed senate
- Amended on third reading (t) 1001a
- Vote reconsidered - restored to third reading
- Returned to senate
Show 17 earlier actions
- Recalled from assembly
- Referred to insurance
- Delivered to assembly
- Passed senateVote 62–0
- Advanced to third reading
- 2nd report cal.
- 1st report cal.164
- Referred to health
- Returned to senate
- Died in assembly
- Referred to insurance
- Delivered to assembly
- Passed senateVote 59–3
- Advanced to third reading
- 2nd report cal.
- 1st report cal.1325
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Stop Delays for HIV Drugs
Assembly Floor Calendar · Sponsor Linda Rosenthal
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
1001--A Cal. No. 164
2023-2024 Regular Sessions
IN SENATE
January 9, 2023
Introduced by Sens. HOYLMAN-SIGAL, MAY, MYRIE, SALAZAR -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- recommitted to the Committee on Health in accordance with Senate Rule 6, sec. 8 -- reported favorably from said committee, ordered to first and second report, ordered to a third reading, passed by Senate and delivered to the Assembly, recalled, vote reconsidered, restored to third reading, amended and ordered reprinted, retaining its place in the order of third reading
AN ACT to amend the insurance law, in relation to prohibiting insurers from restricting or imposing delays in the distribution of antiretroviral prescription drugs to certain persons
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 39 to read as follows:
(39) No policy that provides coverage for antiretroviral prescription drugs prescribed for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) shall subject such drugs to prior authorization.
§ 2. Subsection (l) of section 3221 of the insurance law is amended by adding a new paragraph 22 to read as follows:
(22) Every group or blanket policy delivered or issued for delivery in this state that provides coverage for antiretroviral prescription drugs for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) shall not subject such drug to a prior authorization requirement.
§ 3. Section 4303 of the insurance law is amended by adding a new subsection (vv) to read as follows:
(vv) Any contract issued by a medical expense indemnity corporation, a hospital service corporation or a health services corporation that provides coverage for antiretroviral prescription drugs for the treat-
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD04099-03-4
ment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) shall not subject such drug to a prior authorization requirement.
§ 4. This act shall take effect on the one hundred eightieth day after it shall have become a law.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the insurance law, in relation to prohibiting insurers from restricting or imposing delays in the distribution of antiretrovi- ral prescription drugs to certain persons
Purpose or general idea of bill
The purpose of this bill is to prohibit insurers from utilizing prior authorization that would restrict access to antiretroviral drugs for the treatment or prevention of HIV or AIDS.
Summary of provisions
This bill would prohibit health insurance policies that provides cover- age for antiretroviral prescription drugs prescribed for the treatment or prevention of the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) from subjecting such drugs to prior authorization.
Read the full memo (605 words)
Justification
The "Ending the Epidemic" blueprint and subsequent progress report note that providing better, more immediate access to antiretroviral drugs is a key tool in fighting the AIDS epidemic. Patient needs vary with each individual, and health care providers consider a broad range of factors when selecting treatments including the patient's drug resistance profile, comorbidities, interactions with other medications, and pill burden, in order to determine the most appropriate treatment. A person living with HIV who is on effective HIV treatment can live a long and health life and have effectively no risk of sexually transmitting HIV to others. Additionally, a person at risk for HIV who is on effective HIV prevention medication can reduce their risk of getting HIV by 99% when taking the medication as prescribed.
New York enacted an Antiretroviral (ARV) protected class law in 2005. The 2011 final enacted state budget carved the drug benefit out of fee- for-service and into managed care, and removed statutory protections for ARVs and other drugs, leaving the HIV community with restricted access and life-threatening delays. Because these protections were rolled back, insurers now use protocols such as prior authorization in order to mini- mize prescription drug costs. These protocols have the effect of delay- ing access to these critically important, time-sensitive drugs which are particularly harmful for individuals who are currently living with or seeking to prevent HIV infection.
Restricting access to these life-saving medications undermines the relationship between a healthcare provider and their patient and puts up unnecessary roadblocks to prevention and treatment. Specifically, with HIV treatment, the ability for the patient and medical professional to rapidly switch antiretroviral medications is key to effectively treating and stopping the spread of HIV and AIDS. Patients should have open access to all Single Tablet Regimens (STRs) to fully benefit from current and future advances in HIV therapy. A large body of evidence demonstrates that individuals on STR's have higher levels of adherence to HIV treatment, which improves health outcomes, lowers the risk of hospitalization and reduces overall healthcare costs. Studies show that individuals on STRs within the Veterans Affairs health system, had 46% fewer hospitalizations compared to patients on Multi-tablet Regimens (MTRs) and were 21% more likely to have undetectable levels of HIV in the body. Open access to appropriate HIV prevention and treatment medi- cation for HIV will also support health equity by ensuring that all New Yorkers have their treatment needs met regardless of their insurance plan. This bill will ensure that these important anti-retroviral medica- tions are readily available to patients and not subject to procedural delays so that patients can start an HIV treatment regimen as soon as they are diagnosed or exposed to possible infection.
Prior legislative history
2021-22: A.9580 - Referred to Insurance; S.8423 - Referred to Health
Fiscal implications for state and local governments
None.
Effective date
This act shall take effect on the one hundred eightieth day after it shall have become a law.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.